Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.

Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.

The MAGE-C1/CT7 encodes a cancer/testis antigen (CTA), is located on the chromosomal region Xq26-27 and is highly polymorphic in humans. MAGE-C1/CT7 is frequently expressed in multiple myeloma (MM) that may be a potential target for immunotherapy in this still incurable disease. MAGEC1/CT7 expressio...

Full description

Bibliographic Details
Main Authors: Fabricio de Carvalho, Erico T Costa, Anamaria A Camargo, Juliana C Gregorio, Cibele Masotti, Valeria C C Andrade, Bryan E Strauss, Otavia L Caballero, Djordje Atanackovic, Gisele W B Colleoni
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22110734/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22110734/?tool=EBI

Similar Items